학술논문
Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia.
Document Type
Article
Source
Subject
*CHRONIC lymphocytic leukemia
*CONFIDENCE intervals
*TREATMENT duration
*CANCER relapse
*RETROSPECTIVE studies
*ACQUISITION of data
*PROTON pump inhibitors
*PROTEIN-tyrosine kinase inhibitors
*MEDICAL records
*KAPLAN-Meier estimator
*DESCRIPTIVE statistics
*DRUG utilization
*LONGITUDINAL method
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1444-0903
Abstract
In Australia, over half of patients with relapsed/refractory chronic lymphocytic leukaemia treated with ibrutinib use concomitant proton pump inhibitors (PPIs). High gastric pH reduces the bioavailability of some Bruton tyrosine kinase inhibitors. There was no difference in duration on ibrutinib with or without concomitant PPI (unadjusted P = 0.61; adjusted hazard ratio: 1.23, 95% confidence interval: 0.75–2.02, P = 0.411). PPI use does not affect ibrutinib treatment persistence. [ABSTRACT FROM AUTHOR]